4 Articles
4 Articles
Novo Nordisk, Europe's largest capitalisation company, has achieved worse results than expected in its new slimming drug: Cagrisema
"Ozempic's unexpected increase in demand has presented a challenge in the availability of treatment for people with diabetes, who depend on this medication to control their disease." This was assured by Francisco Pajuelo, medical director of Novo Nordisk Spain, who has pointed out to Medical Writing the measures they have taken from the company to ensure that both people with type 2 diabetes and those with obesity or overweight have adequate the…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
To view factuality data please Upgrade to Premium